Logo
Banner

KRAS inhibitor-10

KRAS inhibitor-10

Catalog No.: PC0043

Size: 5 mg,10 mg, 25 mg,50 mg, 100 mg, 200 mg, 500 mg


Description

KRAS inhibitor 10 selectively and effectively inhibits RAS proteins, specifically KRAS protein. KRAS inhibitor-10 is an orally active anti-cancer drug that can be used in cancer research, such as pancreatic cancer, breast cancer, multiple myeloma, leukemia and lung cancer. KRAS inhibitor-10 is a tetrahydroisoquinoline compound.

Molecular Weight 519.63
Formula C30H37N3O5
CAS No. 2578876-75-0
Appearance Solid
Color White to off-white
SMILES O=C(N1C(C2=CC=C(OC)C=C2C)C3=C(C=C(OC)C(OCCC4=CC=C(OC)C(N)=C4)=C3)CC1)NCC
Shipping Room temperature in continental US; may vary elsewhere.
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
In Vitro KRAS inhibitor-10 (0.1-50 µΜ; 72 hours) has antiproliferative effects in KRas mutant tumor cells, KRAS inhibitor-10 is against A549 (lung carcinoma cell line bearing KRasG12S oncogenic mutation), H358 (non-small cell lung cancer line bearing KRasG12C oncogenic mutation), PANC-1 (epithelioid carcinoma of the pancreas cell line bearing KRasG12D oncogenic mutation) and RPMI (myeloma cell line bearing.
KRasG12A oncogenic mutation) cell proliferation with IC50 values of 0.2 μM, 0.2 μM, 0.1 μM and 0.8 μM, respectively.
KRAS inhibitor-10 (0-1 μM, 7 days) is against cell viability in a 3D CellTiter-GloTM cell viability assay for NIH-H358 cell, the IC50 value is 0.413 μM.
In Vivo KRAS inhibitor-10 (oral administration; 20 mg/kg; BID; 27 days) is safe and tolerate for the bearing mice. KRAS inhibitor-10 demonstrates significant oral anti-tumor activities in vivo. And the tumor growth inhibition (TGI) value is 48.22% for KRAS inhibitor-10.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.